Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Velvet Cichlid on its public offer for Sleep Cycle
Mandate

Vinge advises Velvet Cichlid on its public offer for Sleep Cycle

December 19, 2022 Life Sciences & Health

Velvet Cichlid has announced a public offer to the shareholders of Sleep Cycle AB (publ). The offer values the shares of Sleep Cycle at approximately SEK 862 million.

The Vinge team includes Jesper Schönbeck, Erik Sjöman, Linnéa Sellström, William Kåge, Emma Brolund, Philip Moré and Petter Hellgren (Capital Markets and Public M&A), Louise Brorsson Salomon and Seyran Sahin (Banking and Finance).

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

 Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

 Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025